Abstract
Background: Idiopathic pulmonary fibrosis (IPF)- acute exacerbation (AE) is poorly prognostic and devastating disorder in the IPF management. PMX-DHP (Toraymyxin) is indicated SIRS for endotoxin absorption therapy in Japan, which is widely used with extra cooperative hemo-perfusion and nafamostat mesilate. We tried to use of PMX-DHP for IPF-AE.
Methods: The example of enforcing IPF-AE by PMX-DHP in multicenter experiences (n=73 for IPF in 160, all cases) was retrospectively analyzed. All cases that have P/F data before and after PMX-DHP, and are able to pursue the prognosis until the 90 days, indicated analytical objects.
Results: In comparison of baseline and after PMX-DHP, P/F ratio significantly improved in case of P/F<100 than 100<=P/F<200 at baseline, which was beneficial for survival rate (death rate). P/F ratio actually rose in the survival cases. WBC has decreased in all cases. As for CRP, a significant change was not seen.
Survival rate indicates 66.2% (30d), 30.1% (90d) in all cases, and 70.1% (30d), 34.5% (90d) in IPF. These results suggested to improve survival of IPF-AE in comparison with those reported in the past.
Conclusion: PMX-DHP is possibly beneficial for the prognosis of IPF-AE.
- © 2011 ERS